GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fractyl Health Inc (NAS:GUTS) » Definitions » LT-Debt-to-Total-Asset

Fractyl Health (Fractyl Health) LT-Debt-to-Total-Asset : 0.35 (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Fractyl Health LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Fractyl Health's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.35.

Fractyl Health's long-term debt to total assets ratio increased from Mar. 2023 (0.00) to Mar. 2024 (0.35). It may suggest that Fractyl Health is progressively becoming more dependent on debt to grow their business.

Fractyl Health LT-Debt-to-Total-Asset Historical Data

The historical data trend for Fractyl Health's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fractyl Health LT-Debt-to-Total-Asset Chart

Fractyl Health Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
1.67 0.23 - 0.30 1.10

Fractyl Health Quarterly Data
Dec19 Jun20 Sep20 Dec20 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.94 0.96 1.10 0.35

Fractyl Health LT-Debt-to-Total-Asset Calculation

Fractyl Health's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=83.66/76.212
=1.10

Fractyl Health's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )/Total Assets (Q: Mar. 2024 )
=56.941/163.519
=0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fractyl Health  (NAS:GUTS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Fractyl Health LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Fractyl Health's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Fractyl Health (Fractyl Health) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fractyl Health Inc (NAS:GUTS) » Definitions » LT-Debt-to-Total-Asset
Comparable Companies
Traded in Other Exchanges
N/A
Address
17 Hartwell Avenue, Lexington, MA, USA, 02421
Website
https://www.fractyl.com
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity.